Maravai LifeSciences Holdings, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1] Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint states that Maravai's goodwill was overstated, leading to materially misleading statements about the company's business and prospects [2] Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Maravai investors who have suffered losses to contact them for more information [4]